Genexine has robust R&D pipelines in clinical and pre-clinical stages based on long-acting Fc-fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) co-developed with Handok for both adult and pediatric GHD, currently finished multinational Phase 2 trials and preparing for global Phase 3 trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase 2 in Europe and Korea for Cervical Intraepithelial Neoplasia II/III. Combined with Merck’s Keytruda, GX-188E recently is in Phase 1b/2a trial for cervical cancer. HyLeukin-7 (Immuno-oncology agent, IL-7-hyFc) has finished Phase 1 trial in Korea and received IND approval from US FDA. Currently, Genexine is running more than 7 clinical trials globally. In addition to collaboration with Merck, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Simcere Pharma, Kalbe Pharma, and Korean big Pharma companies such as Handok, Green Cross and Yuhan. More information can be found at www.genexine.com
View Top Employees from Genexine, Inc.Website | http://www.genexine.com |
Revenue | $11 million |
Employees | 47 (44 on RocketReach) |
Founded | 1999 |
Phone | +82 31-628-3200 |
Fax | +82 31-628-3229 |
Technologies |
JavaScript,
HTML,
Google Analytics
+2 more
(view full list)
|
Industry | Biotechnology Research, Chemicals, Petrochemicals, Glass & Gases, Artificial Intelligence, Manufacturing, Data and Analytics, Science and Engineering, Software, Biotechnology, Medical, Health Care |
Web Rank | 11 Million |
Keywords | Genexine, Genexine, Inc. |
Competitors | Ambrx, Ascendis Pharma, Inhibrx, Inc., JCR Pharmaceuticals Co Ltd, Prothena Corporation plc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325414 Companies |
Looking for a particular Genexine, Inc. employee's phone or email?
The Genexine, Inc. annual revenue was $11 million in 2024.
Sung-June Hong is the CEO of Genexine, Inc..
44 people are employed at Genexine, Inc..
The NAICS codes for Genexine, Inc. are [325, 32541, 32, 3254, 325414].
The SIC codes for Genexine, Inc. are [283, 28].